Vanguard Fiduciary Trust
CADL icon

Vanguard Fiduciary Trust’s Candel Therapeutics CADL Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.24M Buy
412,109
+131,658
+47% +$995K ﹤0.01% 2272
2026
Q1 		$1.37M Buy
+280,451
New +$1.53M ﹤0.01% 2762

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Fiduciary Trust's CADL Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Candel Therapeutics (CADL) stake by 47% in Q2 2026, buying an estimated $995K and bringing the position to 412,109 shares worth $4.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2272.

Vanguard Fiduciary Trust first reported a position in CADL in Q1 2026 and has held it in 2 quarters since. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Vanguard Fiduciary Trust held 412,109 shares of Candel Therapeutics worth $4.24M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 131,658 Candel Therapeutics shares in Q2 2026, an estimated $995K.
  • Candel Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2272 holding.
  • Vanguard Fiduciary Trust first reported a position in Candel Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.